Allstate Investment Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Allstate Investment Management’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	$3.12M	Buy	+4,323	New	+$3.19M	0.09%	145

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Allstate Investment Management's REGN Position: Q4 2022 in Review

Allstate Investment Management opened a new position in Regeneron Pharmaceuticals (REGN) in Q4 2022: 4,323 shares worth $3.12M. The stake represents 0.09% of the portfolio and ranks #145 among its holdings.

1,158 funds tracked by Wall St. Rank hold REGN as of Q4 2022.

Allstate Investment Management held 4,323 shares of Regeneron Pharmaceuticals worth $3.12M as of Q4 2022.
Regeneron Pharmaceuticals was a new Allstate Investment Management position in Q4 2022.
Regeneron Pharmaceuticals made up 0.09% of Allstate Investment Management's portfolio in Q4 2022, its #145 holding.
1,158 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2022.

Based on Allstate Investment Management's 13F filing for Q4 2022, filed 14 Feb 2023.